Form D · Biotechnology
XORI Corp
Seattle, WA · CIK 0001463974
Offering snapshot reported May 15, 2009 · SEC filing
- Reported sold
- $2.1M Offering amount: $4.52M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2009 | Amendment | $2,102,396 | No comparison | Not reported | SEC filing |
| May 15, 2009 | Initial | $2,102,396 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-131262
Source: Form D, filed May 15, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Eshelman | Director |
| Steve Gillis | Director |
| Thong Le | Director |
| Stuart J. Mackey | Director |
| Nancy Maizels | Director |
| Lindsay Rayle | Executive |
| David Schubert | Executive |
| Chad Waite | Director |
| Carl Weissman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 East Lake Ave, E Suite 205
Seattle, WA, 98102
Seattle, WA, 98102